EC-17

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C42H36N10O10S
Molecular Weight	872.861
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)CC[C@H](N(CCNC(=S)NC1=CC2=C(C=C1)C3(OC2=O)C4=C(OC5=C3C=CC(O)=C5)C=C(O)C=C4)C(=O)C6=CC=C(NCC7=CN=C8N=C(N)NC(=O)C8=N7)C=C6)C(O)=O

InChI

InChIKey=ZMTAPBHUSYTHBY-PMERELPUSA-N

InChI=1S/C42H36N10O10S/c43-33(55)12-11-30(38(58)59)52(37(57)20-1-3-21(4-2-20)46-18-23-19-47-35-34(48-23)36(56)51-40(44)50-35)14-13-45-41(63)49-22-5-8-27-26(15-22)39(60)62-42(27)28-9-6-24(53)16-31(28)61-32-17-25(54)7-10-29(32)42/h1-10,15-17,19,30,46,53-54H,11-14,18H2,(H2,43,55)(H,58,59)(H2,45,49,63)(H3,44,47,50,51,56)/t30-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C42H36N10O10S
Molecular Weight	872.861
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/folate-fitc | https://www.ncbi.nlm.nih.gov/pubmed/23603861 | https://www.ncbi.nlm.nih.gov/pubmed/24714357 | https://www.ncbi.nlm.nih.gov/pubmed/26541080 | https://www.ncbi.nlm.nih.gov/pubmed/27014973 | https://www.ncbi.nlm.nih.gov/pubmed/28497233 | https://adisinsight.springer.com/drugs/800041273

EC17 (also known as Folate-FITC) is conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. EC17 binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity. EC17 is participating in phase II clinical trials for the treatment of patients with endometrial cancer, endometriosis, lung cancer, renal cell carcinoma. In January 2018, On Target Laboratories initiated a phase III trial to evaluate the safety and efficacy of EC17 injection for patients with ovarian cancer.

Originator

Approval Year

PubMed

Title	Date	PubMed
A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma.	2013 May	23603861
A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.	2014 May	24714357
Intraoperative Molecular Diagnostic Imaging Can Identify Renal Cell Carcinoma.	2016 Mar	26541080
Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17.	2016 May 31	27014973
Standardization and Optimization of Intraoperative Molecular Imaging for Identifying Primary Pulmonary Adenocarcinomas.	2018 Feb	28497233
Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies.	2019	30941303

Sample Use Guides

In Vivo Use Guide

Patients received 0.1 mg/kg EC17 intravenously over 10 minutes, 2-3 hours before surgery.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Sat Dec 16 03:01:47 UTC 2023` Edited by `admin` on `Sat Dec 16 03:01:47 UTC 2023`
Record UNII	V7YQ6134AE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EC-17

Common Name

English

EC17 (FOLATE-FITC)

Common Name

English

L-GLUTAMINE, N2-(4-(((2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-N-(2-((((3',6'-DIHYDROXY-3-OXOSPIRO(ISOBENZOFURAN-1(3H),9'-(9H)XANTHEN)-5-YL)AMINO)THIOXOMETHYL)AMINO)ETHYL)-

Common Name

English

EC 17 [WHO-DD]

Common Name

English

FOLATE-FITC

Common Name

English

FOLATE-FLUORESCEIN CONJUGATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1455